Press Releases Check out the latest news from Tavanta May 31, 2023 Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses May 24, 2023 Tavanta Therapeutics Announces New Preclinical Data for its Cystic Fibrosis Candidate TAVT-135 at Two Prominent Scientific Conferences January 05, 2023 Tavanta Therapeutics Announces Positive Top-line Results from Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer October 28, 2022 Tavanta Therapeutics to Present Preclinical Data for TAVT-135 at the North American Cystic Fibrosis Conference August 01, 2022 Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer July 12, 2021 Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer August 31, 2020 Tavanta Therapeutics, a New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-balanced Approach to Product Development 123>>
